PO.IM01.15 · 免疫学
Monoclonal Antibodies and Antibody-Cytokine Platforms
-
- 4331 4331 ZL-1222, a PD-1-targeted potency-reduced IL-12 immunocytokine, overcomes PD-1 resistance and enhances antitumor immunity with an accepted safety profile Cathy Wang, Lina Wang, Xue Wang, Xinchuan Dai, Qiuping Ye, Wilson Peng, Ziruo Wen, Lei Wang, Changwei Lv, Min Chen, Donghui Li, Qidong Hu, Bing Wan, Linda N. Liu
- 4332 4332 AR166, a first-in-class PD-1xLAG-3xIL-2v tri-specific immunocytokine delivering Cis -acting IL-2v to overcome immune checkpoint inhibitor resistance Jaeho Song, Seon-mi Yu, Jae-Seok Lee, Jinkeol Mok, WooJeong Lee, Seo-Young Koo, Ye Rim Gu, Min-Young Park, Seoyun Yang, Juhan Yoon, Young Woo Park, Wooick Jang, Su-Hyung Park
-
-
- 4335 4335 JMB2403, a potential best-in-class PD-1-dependent IL2Rbetagamma-targeting tri-specific antibody for safe and potent immunotherapy Chunyin Gu, Deyi Wang, Yan Wang, Fangfang Jia, Fu Zhou, Shun Chang, Yu Zhao, Linlin Liu, Huawei Zhang, Peipei Liu, Xiaodan Cao, Taylor B. Guo
-
- 4337 4337 TGI-17b: A potential first-in-class PD-1/VEGF/IL-2 alpha-bias trispecific antibody and the potential next generation cornerstone for pan-cancer therapy Guoshuai Cao, Yangyang Li, Yuwei Wu, Haoyu Sun, Zhigang Tian
-
-
- 4340 4340 AZD6750, a CD8alpha-guided IL-2 immunocytokine effectively combines with rilvegostomig, a PD-1/TIGIT bispecific antibody, to enhance endogenous immunity Matthew J. Elder, Aidan H. Riley, Sin Lih Tan, Jerome Mastio, Bruno Frederico, Fabien Garcon, Hena Khalique, Georgina Bowyer, Paul Chariou, Nicholas M. Durham, Maria Broggi, Emily Hsiue, Simon Rodney, Jonathan B. Fitzgerald, Nadia Luheshi, Mark Cobbold, Saso Cemerski, Simon J. Dovedi
- 4341 4341 A novel alphaPD-1/alphaVEGF/IL-21v tri-specific fusion protein exhibits potent antitumor efficacy beyond alphaPD-1/alphaVEGF bispecific therapy Suna Kim, Sunjung Cho, Hyojoo Bang, So Woon Kim, Yongjun Jung, Seokchan Kang, Suyoon Kim, Mi-Seong Kim, Jun-Eui Park, Young Jin Park, Sungyoub Jung
-
- 4343 4343 A novel anti-PD-1/IL-15 fusion protein JMT108 (SYS6090) with highly selective PD-1⁺ immune cell activation and potent anti-tumor efficacy Ke He, Yushan Kong, Jun Mu, Hongyan Wang, Yisha She, Yanfang Su, Yi Fan, Liping Song
-
-
-
-
- 4348 4348 Anticancer activity of a humanized anti-VEGFR-1 monoclonal antibody and its derived antibody-drug conjugates targeting tumor cells and tumor-microenvironment components Pedro M. Lacal, Maria Grazia Atzori, Claudia Ceci, Federica Ruffini, Sonia Valentini, Lauretta Levati, Grazia Graziani
-
-
-
-
- 4353 4353 PHST001, a humanized anti-CD24 hIgG4 antibody, is effective against metastatic tumors and retains its anti-tumor activity in the presence of competing IgG Suzana A. Kahn, Joseane Sampaio, Douglas V. Faget, Rachel E. Brewer, Giovanni C. Forcina, Blacker Grace, Priyanka R. Malusare, Alexandria Beans, Seth D. Ludwig, John S. Burg, Jennifer Yinuo Cao, Raphaël F. Rousseau, Amira A. Barkal, Ravi Majeti, Irving L. Weissman, Roy L. Maute
-
- 4355 4355 Cryo EM-based structural characterization of IMC-002, a next-generation anti-CD47 antibody with a unique binding site and biomarker candidates, supporting evidence of enhanced safety and efficacy Hyesun Lee, Jiyea Choi, HyeHyeon Jang, Heewook Shin, Jiyoung Yoon, Woochan Hwang, Sung Ho Kim, Heung Tae Kim
-
-
